Clinical Trial Update: Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of osimertinib and capivasertib in patients with advanced non-small cell lung cancer harboring PIK3CA/AKT1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Shanxi Province Cancer Hospital | Conditions: Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING